N-(2,4-difluoro-3-((3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)phenyl)pyridine-3-sulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N-(2,4-difluoro-3-((3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)phenyl)pyridine-3-sulfonamide
• 英文别名: N-[2,4-difluoro-3-[2-[3-(4-fluorophenyl)-2H-pyrazolo[3,4-b]pyridin-5-yl]ethynyl]phenyl]pyridine-3-sulfonamide
• 化学式: C₂₅H₁₄F₃N₅O₂S
• 分子量: 505.48
• InChiKey: BMIRKZGQCVLNBO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  36
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  5-溴-1H-吡唑[3,4-B]吡啶 在 potassium phosphate 、 N-碘代丁二酰亚胺 、 copper(l) iodide 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 三叔丁基膦 、 sodium hydride 、 potassium carbonate 、 三氟乙酸 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 二氯甲烷 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 、 mineral oil 为溶剂， 反应 31.5h， 生成 N-(2,4-difluoro-3-((3-(4-fluorophenyl)-1H-pyrazolo[3,4-b]pyridin-5-yl)ethynyl)phenyl)pyridine-3-sulfonamide
  参考文献：
  名称：

  N-(3-Ethynyl-2,4-difluorophenyl)sulfonamide Derivatives as Selective Raf Inhibitors

  摘要：

  A series of N-(3-ethynyl-2,4-difluorophenyl)sulfonamides were identified as new selective Raf inhibitors. The compounds potently inhibit B-Raf(V600E) with low nanomolar IC50 values and exhibit excellent target specificity in a selectivity profiling investigation against 468 kinases. They strongly suppress proliferation of a panel of human cancer cell lines and patient-derived melanoma cells with B-Raf(V600E) mutation while being significantly less potent to the cells with B-Raf(WT). The compounds also display favorable pharmacokinetic properties with a preferred example (3s) demonstrating significant in vivo antitumor efficacy in a xenograft mouse model of B-Raf(V600E) mutated Colo205 human colorectal cancer cells, supporting it as a promising lead compound for further anticancer drug discovery.

  DOI：

  10.1021/acsmedchemlett.5b00039

文献信息

• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20190169166A1

  公开（公告）日：2019-06-06

  Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

  提供的是一种可能具有GCN2抑制作用的杂环化合物，预计可用于预防或治疗与GCN2相关的疾病，包括癌症等。一种由以下式（I）表示的化合物： 其中每个符号如描述中所述，或其盐。
• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10696651B2

  公开（公告）日：2020-06-30

  Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

  本文提供了一种杂环化合物，它可能具有 GCN2 抑制作用，有望用于预防或治疗与 GCN2 有关的疾病，包括癌症等。由式（I）代表的化合物： 其中各符号如说明书所述，或其盐类。
• A novel photocaged B-RafV600E inhibitor toward precise melanoma treatment
  作者：Zhiyuan Chen、Ran Ke、Zhiqiang Song、Yang Zhou、Xiaomei Ren、Weixue Huang、Zhen Wang、Ke Ding

  DOI：10.1016/j.bmcl.2022.128683

  日期：2022.5
• Phosphatase Binding Compounds and Methods of Using Same
  申请人：Yale University

  公开号：US20200268897A1

  公开（公告）日：2020-08-27

  The present invention provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Such target proteins can be any protein involved in the pathway of a disease or disorder, such as but not limited to cancer, neurodegeneration, metabolic disease, diabetes, insulin resistance, and so forth.